Association between PD-1 single nucleotide gene variants and the risk of metastatic melanoma
Andrea Boutros(The University of Sydney), Francesco Spagnolo(Martin University), Maria Pia Pistillo(Ospedale Policlinico San Martino), Elena Croce(Ospedale Policlinico San Martino), Anna Morabito(Ospedale Policlinico San Martino), Barbara Banelli(Ospedale Policlinico San Martino), Edoardo Raposio(University of Parma), Paola Queirolo, Roberta Carosio(Ospedale Policlinico San Martino), Enrica T. Tanda(Ospedale Policlinico San Martino), Vincenzo Fontana(Ospedale Policlinico San Martino), Dalila Campanella(Ospedale Policlinico San Martino)
Cited by 5
Related Papers
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2017|491
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
|The Lancet Oncology|2021|389
CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction
|International Journal of Cancer|2005|322
Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility
|Nature Genetics|2020|238
The treatment of advanced melanoma: Current approaches and new challenges
|Critical Reviews in Oncology/Hematology|2024|140